Skip navigation

Silence Therapeutics Announces Leadership Change

05 June 2018

4 June 2018 - Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases, announces today that Ali Mortazavi is stepping down as Chief Executive Officer and as a Director of the Company with immediate effect after having served the Company for six years. Dr Annalisa Jenkins, Chair of Silence Therapeutics, is today assuming the role of Executive Chair in an interim capacity to ensure a smooth transition until a new Chief Executive Officer is appointed. 


Annalisa Jenkins, Executive Chair of the Board of Directors, said: “On behalf of the Board I would like to thank Ali for his achievements and commitment to Silence over the past six years. Under his leadership Silence has built an experienced international executive team with significant RNAi expertise that has established a strong IP and technology platform in GalNAC-based siRNA. We believe today that our RNAi platform and R&D capabilities offer an opportunity to advance our lead programme in iron metabolism towards the clinic and to establish research partnerships that will maximise shareholder value. We wish Ali every success in his future endeavours."

Dr Jenkins, MBBS, FRCP, joined Silence as Non-Executive Chair in October 2017. She is the CEO of Plaquetec and serves on a number of UK and International Life Science boards. She has 25 years of international experience in building and leading teams that advanced programmes from scientific research through clinical development, regulatory approval and into healthcare systems globally. Previous roles include positions as Head of Global R&D for Merck Serono and Head of Global Medical Affairs for Bristol-Myers Squibb. She also has recent experience in the fields of gene therapy and rare diseases, having served as the CEO of Dimension Therapeutics, Inc., until its acquisition in late 2017.

Enquiries:

Silence Therapeutics plc
Annalisa Jenkins, Executive Chair
David Ellam, Chief Financial Officer
Tel: +44 (0) 20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/ Oliver Jackson
Tel: +44 (0) 20 7418 8900

Media & IR Enquiries:

Optimum Strategic Communications  
Mary Clark/ Eva Haas/ Hollie Vile
silence@optimumcomms.com

Tel: +44 (0) 20 3714 1789

IR Enquiries – US:

Burns McClellan
John Grimaldi    
silence.therapeutics@burnsmc.com
Tel: +1 (212) 213 0006